he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:哪些抗菌药物可出现异常癫痫?
下一页:得癫痫病的病征有哪些
- 2022-04-212013年国际抗癫痫联合会抗癫痫制剂使用指南
- 2021-11-03复杂性癫痫癫痫病预防的方法
- 2019-04-19原发性癫痫疾病的病因
- 2019-04-17癫病医院哪家治疗效果好
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 2015 神经系统疾病诊疗进展
- UCB的Vimpat癫痫新适应症在美国获批
- 2016AAN:神经专家发表了有前途的专业见解
- 抗癫痫药物预防新发癫痫:任重而道远
- 癫痫治疗障碍仍难以克服
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 预测癫痫患者再入院风险
- 泡温泉时不能忽视的事情
- 癫痫的常见症状是什么?
- DCR: 慢性肾病对局部晚期直肠癌患者接受新辅助放化疗的预后影响
- 不注意这些问题,吃多少药都没用!
- 2013国际抗癫痫联合会抗癫痫药用指南
- 北京癫痫手术费用
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 心率多少正常 如何保持正常心率不变
- 癫痫会遗传吗 癫痫的治疗方法
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 癫痫治愈费用
- 癫痫患者手术评估新型工具
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 癫痫猝死:凶手是谁?
- 癫痫治疗 中医治疗癫痫不用担心
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 2015第31届国际癫痫大会(IEC)
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- 综述:癫痫持续状态诊治最新进展
- 引起癫痫病心脏病的因素有哪些
- 怎么病患癫痫病
- 招致癫痫病发病原因
- 癫痫病还能有的病人
- 治疗癫痫病比较好的分析方法是什么
- 痉挛病到底有哪几种类型呢 痉挛的症状有什么
- 具体内容的癫痫病病因有哪些
- 新型“基本功能”用于癫痫患者手术评估
- 略微癫痫病要花多少钱
- 病者癫痫病会严重吗
- 病人癫痫病最佳
- 癫痫病的最佳治疗方式则
- 怎么用生物科学的方法治疗癫痫病